Skip to main content

David Costill

Managed Care Q&A
08/30/2017
Virginia Gurley, MD, chief medical officer at AxisPoint Health, discusses population health strategies that payers can employ to achieve the Triple Aim of improving health outcomes while reducing costs.
Virginia Gurley, MD, chief medical officer at AxisPoint Health, discusses population health strategies that payers can employ to achieve the Triple Aim of improving health outcomes while reducing costs.
Virginia Gurley, MD, chief...
08/30/2017
First Report Managed Care
Managed Care Q&A
04/18/2017
An Interview with Robert Bruce, vice president of reimbursement at Clinical Genomics
An Interview with Robert Bruce, vice president of reimbursement at Clinical Genomics
An Interview with Robert Bruce,...
04/18/2017
First Report Managed Care
News
06/12/2017
As pharmacy benefit managers negotiate deep discounts for reference biologics, biosimilar prices are not making the spending impact that payers had hoped for. 
As pharmacy benefit managers negotiate deep discounts for reference biologics, biosimilar prices are not making the spending impact that payers had hoped for. 
As pharmacy benefit managers...
06/12/2017
First Report Managed Care
Managed Care Q&A
07/03/2017
Snezana Mahon, PharmD, vice president, clinical product development at Express Scripts, discusses the design of Express Scripts' opioid solution.
Snezana Mahon, PharmD, vice president, clinical product development at Express Scripts, discusses the design of Express Scripts' opioid solution.
Snezana Mahon, PharmD, vice...
07/03/2017
First Report Managed Care
Managed Care Q&A
03/03/2017
Rami Doukky, MD, MSc, speaks about the development of appropriate use criteria for cardiac imaging and the implementation of laws mandating their use.
Rami Doukky, MD, MSc, speaks about the development of appropriate use criteria for cardiac imaging and the implementation of laws mandating their use.
Rami Doukky, MD, MSc,...
03/03/2017
First Report Managed Care
News
03/17/2017
New guidance from the FDA clarifies the expectations for drugmakers looking to demonstrate interchangeability between a biosimilar and its reference product.
New guidance from the FDA clarifies the expectations for drugmakers looking to demonstrate interchangeability between a biosimilar and its reference product.
New guidance from the FDA...
03/17/2017
First Report Managed Care